Xspray Pharma gets go-ahead from the Swedish MPA for clinical study

On June 21, 2018 Xspray Pharma reported the company has obtained approval from the Swedish Medical Products Agency (MPA) to carry out a previously announced clinical study of the formulation of the company’s product candidate HyNap-Dasa (Press release, Xspray, JUN 21, 2018, View Source [SID1234650102]). The study is part of Xspray’s clinical program and will be completed during the third quarter. The objective is to confirm the bioequivalence of the optimized formulation developed by Xspray, based on the company’s patented RightSize-technology.
"We are pleased with the progress of the project and following the decision of the MPA, we can now proceed with our plan for clinical studies," commented Per Andersson, CEO of Xspray Pharma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The current study is intended to confirm the formulation of the product candidate HyNap-Dasa. The results will form the basis of the following registration studies. The results from the current study are expected to be available by the end of the third quarter.

HyNap-Dasa is the first in a portfolio of product candidates that Xspray Pharma is developing with the target to haver products ready to launch on the US market during 2020-2026. All of the product candidates in the portfolio are versions of cancer drugs currently on the market, based on protein kinase inhibitors (PKI) and used for cancer treatments.

NANOBIOTIX ANNOUNCES POSITIVE PHASE II/III TOPLINE DATA
IN SOFT TISSUE SARCOMA WITH NBTXR3

On June 21, 2018 NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, reported positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS) (Press release, Nanobiotix, JUN 21, 2018, View Source [SID1234527418]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Data are exceptional and show without any doubt an improvement of radiation therapy impact with a significant
number of complete response. NBTXR3 can bring real benefit to patients and it can change the standard of care.
This innovation will play a role in many other indications and particularly where radiotherapy is used alone."
Pr. Sylvie Bonvalot, MD, Head of Sarcoma and Complex Tumor Surgery Unit at Institut Curie, Paris, France and
Global Principal Investigator of the PII/III study NBTXR3 is a first-in-class product with a new mode of action physically destroying cancer cells when activated by radiation therapy. NBTXR3 is designed to directly destroy tumors and activate the immune system for both local control and systemic disease treatment.

The Phase II/III study was a prospective, randomized (1:1), multinational, open label and active controlled twoarmed
study of 180 patients with locally advanced STS. The objective of the Phase II/III trial was to evaluate the
efficacy and the safety of NBTXR3 activated by radiotherapy compared to the standard of care (radiotherapy
alone). Patients have been treated with the standard dose of radiation (25×2 Gy) and efficacy endpoints have
been measured on surgically resected tumors.

Primary endpoint achieved in the intend-to-treat population (ITT)

The primary endpoint isthe pathological Complete Response Rate (pCRR) defined asthe rate of patients showing
less than 5% of residual viable cancer cells in the tumor post treatment. This primary endpoint is related to
NBTXR3’s mode of action and product efficacy. Twice as many patients (16.1% vs 7.9%) achieved a pathological
Complete Response (pCR) with NBTXR3 compared to the control arm (p = 0.0448). The significant difference
observed between both arms validates the superiority of the treatment with NBTXR3 versus radiation alone.
Secondary Endpoint achieved in the ITT – Resection margins status and operability
The main secondary endpoint is the resection margin status evaluating the quality of surgery. The main objective
is to achieve compartmental clean margins (negative margin defined as R0) i.e. no more cancer cells found within
the surgical margins. NBTXR3 demonstrated a statistically significant increase in R0 surgical margin rate
compared to radiotherapy alone (relative increase of 20%, p = 0.042). The resection with negative margins is a
validated surrogate endpoint for systemic and long-term benefit for patients such as local progression free
survival (PFS) and distant PFS.

Pr Jean-Yves Blay, MD, Director of the Centre Léon Bérard, Lyon, France, commented, "I am amazed by the
difference of Response Rate, it is extremely uncommon to double the Rate of Complete histological Response and
I do not see any other strategy able to accomplish that. Even more impressive is the R0 rate, which is increased
by more than 20% compared to an average rate of 64%. This difference is really impressive, considering that R0
impacts patients relapses and survival."

Safety and feasibility
NBTXR3 demonstrated a good local tolerance among this patient’s population. Findings showed a very similar
radiation-related safety in both arms. The patients in both the control and tested arms of the study received the
planned radiotherapy (dose and schedule).
Notably, feasibility and follow-up of surgery were also equivalent. Acute immune adverse events of short
duration observed in 7.9% of patients.
The Injection site caused pain in 13.5% of patients. In addition, 6.7% of patients experienced grade 1 injection
site hematoma / ecchymosis.
Regarding long-term toxicity, less serious adverse events were reported for NBTXR3 arm.
Regulatory strategy and CE mark
The positive results from this study support and further validate the European regulatory strategy of the
previously submitted CE marking application in STS. The company will submit the new data as a supplement to
the European Notified Body in a timely manner.

Next steps
The Company will present the results at an upcoming international medical conference.
The clinical validation of NBTXR3’s physical mode of action in a very heterogeneous and hard-to-treat disease
strengthens the universal profile of the product and confirms the development strategy in multiple indications.
Currently, the company is evaluating NBTXR3 in seven clinical trials with a focus on head and neck cancers and
Immuno-Oncology programs.

David Raben MD, Professor of Radiation Oncology, University of Colorado Cancer Center, CO, USA, commented,
"These results from a Phase III study are impressive in a notoriously difficult disease like Soft Tissue Sarcoma.
These cancers are generally less sensitive to radiation and previous attempts to improve local control with chemoradiation regimens were considered too toxic. This study substantiates the medical benefit of safely enhancing
the effect of radiation therapy with novel physics-based approaches delivered locally within the cancer. In
addition, this product may potentiate a pro-inflammatory environment suitable for immune enabling or DNA
damage inhibitor drugs. These findings set the foundation for additional studies in areas such as head and neck
cancer and perhaps in areas such as high-risk prostate, bladder or pancreas cancer."
Webcast and dial-in (English) June 22 at 4pm Paris time: View Source
For more information about the STS study: www.clinicaltrial.gov (Identifier: NCT02379845)
View Source
***
About PII/III clinical trial (act.in.sarc study)
Nanobiotix and its partner, PharmaEngine recruited 180 patientsin 43 sites across 13 countriesin Europe and Asia. The Global
Principal Investigator is Pr. Sylvie Bonvalot, MD, PhD (Institut Curie, Paris, France).
Primary endpoint
Pathological complete response rate (pCRR): A pathological Complete Response is defined as the presence of less than 5%
of residual malignant viable cells in the surgically removed tissue. The primary endpoint compared the proportion of patients
presenting pathological Complete Response (pCR) between the two arms. This was determined by an independent
pathological central review according to EORTC score (Wardelmann et al., 2016).
Main secondary endpoint
Resection margin status: The resection margin status is evaluating the quality of surgery. Surgery remains the mainstay of
care for locally advanced soft tissue sarcoma. The primary surgical objective is the complete removal of the tumor with
negative resection margins (R0). Several retrospective studies suggest that surgical margin status predict the risk of local and
distant recurrence. In particular, negative surgical margins are significantly correlated to increased patients’ survival.

About NBTXR3
NBTXR3 is a first-in-class product designed to destroy, when activated by radiotherapy:
• tumors through physical cell death
• metastasis due to immunogenic cell death leading to activation of the immune system.
NBTXR3 has a high degree of biocompatibility, requires one single administration before the whole radiotherapy treatment and has the ability to fit into current worldwide standards of radiation care.
NBTXR3 is actively being evaluated in head and neck cancer with locally advanced squamous cell carcinoma of the oral cavity or oropharynx in elderly and frail patients unable to receive chemotherapy or cetuximab with very limited therapeutic options. The Phase I/II trial has already delivered very promising results regarding the local control of the tumors.

Nanobiotix is running an Immuno-Oncology development program . In the U.S., the Company received the FDA’s approval to launch a clinical study of NBTXR3 activated by radiotherapy in combination with anti-PD1 antibodies in lung, and head and neck cancer patients (head and neck squamous cell carcinoma and non-small cell lung cancer).
The other ongoing studies are treating patients with liver cancers (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma.

The first market authorization process (CE Marking) is ongoing in Europe in the soft tissue sarcoma indication

Abbott Hosts Conference Call for Second-Quarter Earnings

On June 20, 2018 Abbott (NYSE: ABT) reported that it will announce its second-quarter 2018 financial results on Wednesday, July 18, 2018, before the market opens (Press release, Abbott, JUN 20, 2018, View Source [SID1234527401]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott’s Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.

Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men

On June 20, 2018 Atossa Genetics Inc. (ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, reported that it has completed dosing and clinical visits in its Phase 1 study of its proprietary topical Endoxifen in men (Press release, Atossa Genetics, JUN 20, 2018, View Source [SID1234527402]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are now proceeding to the final stages of this study, which are to complete analysis of blood samples and then collect and analyze the data," commented Steve Quay, Ph.D., M.D., President and CEO of Atossa. "We expect to report preliminary results from the study in the next quarter," added Dr. Quay.

The objectives of the placebo-controlled, repeat dose study of 24 healthy male volunteers are to assess the pharmacokinetics of a proprietary topical Endoxifen dosage form over 28 days, as well as to assess safety and tolerability.

Atossa is developing topical Endoxifen for a condition in men called gynecomastia, which is male breast enlargement. According to the Mayo Clinic, 25% of men in the U.S. between the ages of 50-69, or approximately 10 million men, suffer from gynecomastia. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone is low compared to estrogen. For example, in prostate cancer treatment, testosterone is suppressed with androgen deprivation therapy resulting is higher estrogen levels that usually triggers gynecomastia. One recent study indicates that up to 90% of men taking androgen deprivation therapy suffer from gynecomastia and breast pain (Handoo Rhee, et al., October 18, 2014, BJU International). There is no FDA-approved pharmaceutical to treat gynecomastia. Current therapeutic approaches in these patients include the daily use of oral estrogen-suppressing medications and prophylactic breast bud irradiation which is often repeated.

Atossa’s Proprietary Endoxifen

Endoxifen is an active metabolite of tamoxifen. Tamoxifen is an FDA-approved drug to prevent new breast cancer as well as recurrent breast cancer in breast cancer patients. Tamoxifen itself must be broken down by the liver into active compounds (metabolites), of which Endoxifen is the most active. Many patients taking tamoxifen, however, do not properly metabolize tamoxifen into therapeutic levels of Endoxifen.

Atossa has completed a comprehensive Phase 1 clinical study using both a topical and an oral formulation of Endoxifen in women. Results from the topical arm of the Phase 1 study in women indicated that the topical formulation was safe, well tolerated and that topical Endoxifen crossed the skin barrier in a dose-dependent fashion.

Topical Endoxifen Opportunities

In addition to gynecomastia, Atossa is also developing its proprietary topical Endoxifen to reduce Mammographic Breast Density (MBD), which has been shown in studies conducted by others to be an independent risk factor for developing breast cancer. To date, 34 U.S. states have enacted laws requiring that findings of MBD be communicated to the patient. And according to the National Cancer Institute, approximately 10 million women in the U.S. have high breast density (BI-RADS level C or D with "D" being the highest). Although oral tamoxifen has been shown to reduce MBD, the benefit-risk ratio is generally not acceptable to most patients. For example, it is estimated that only ~ 2% of women at high-risk of developing breast cancer, including those with MBD, take oral tamoxifen to prevent breast cancer because of the risks of, or actual side-effects of, oral tamoxifen. There is no FDA-approved treatment for MBD.

Atossa is planning a Phase 2 study of its topical Endoxifen in women with MBD. The study will be conducted at Stockholm South General Hospital in Sweden and will be led by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet.

The primary endpoint of this study is to determine if topical Endoxifen administration results in an individual change in MBD, which will be measured after three and six months. Secondary endpoints are safety and tolerability. The objective of the study is to determine the effect size on MBD between the placebo and active groups, which will permit sample size calculations in a future Phase III study. Enrollment is anticipated to be completed by the end of 2018.

TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody

On June 20, 2018 TG Therapeutics, Inc. (NASDAQ:TGTX) and Novimmune SA, reported that the companies have entered into an exclusive global agreement to collaborate on the development and commercialization of Novimmune’s novel first-in-class anti-CD47/anti-CD19 bispecific antibody known as TG-1801 (previously NI-1701) (Press release, TG Therapeutics, JUN 20, 2018, View Source [SID1234527404]). The companies will jointly develop the product on a worldwide basis, focusing on indications in the area of hematologic B-cell malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TG Therapeutics will make up-front and milestones payments based on early clinical development, and will be responsible for the costs of clinical development of the products through the end of Phase II, after which TG Therapeutics and Novimmune will be jointly responsible for all development and commercialization costs of the product. TG Therapeutics and Novimmune will each maintain an exclusive option, exercisable at specific times during development, for TG Therapeutics to license the rights to TG-1801, in which case Novimmune will be eligible to receive additional payments contingent on certain clinical, regulatory and commercial milestones, totaling approximately $185MM as well as tiered royalties on net sales.

TG-1801, a fully-human IgG1, designed to target and deplete B-cells via multiple mechanisms, is based on Novimmune’s kappa-lambda -body format which allows preservation of all favorable properties of a conventional monoclonal antibody while adding bispecific functionalities. One mechanism unique to this bispecific antibody involves blocking of CD47 referred to as the "do not eat me" signal for the body’s phagocytic cells specifically directed to CD19 positive cells. The net effect is highly targeted, potent anti-B-cell tumor phagocytic activity, while avoiding the general toxicity concerns associated with earlier agents targeting the CD47 pathway. Moreover, the co-targeting of CD19 is not only expected to enhance safety but by retaining its IgG1 Fc functionality, this agent is designed to provide a secondary mechanism of anti-tumor activity through the induction of antibody dependent cellular cytotoxicity (ADCC).

TG-1801 is expected to be the first anti-CD47 bispecific antibody worldwide that will go into clinical trials, which are expected to commence later this year or early in 2019.

"We are delighted to see our first bispecific antibody move forward into the clinic with an experienced partner in the field of hematological malignancies, and to provide proof of principle for our completely novel approach," said Chairman and Chief Executive Eduard Holdener. "We are excited about the potential benefit that this new approach could bring to B-cell lymphoma patients."

"We are excited to enter into this collaboration with Novimmune, a leader in antibody engineering, and whose innovations in the field of CD47 bispecific antibodies have generated a potentially more effective and safer approach for targeting of CD47, which was recently validated in the clinical studies as a very promising pathway for tumor targeting, especially in combination with anti-CD20 monoclonal antibodies," stated Michael S. Weiss, Executive Chairman and CEO of TG Therapeutics. Mr. Weiss continued, "TG Therapeutics is focused on building the most comprehensive and effective portfolio for the treatment of hematologic malignancies and autoimmune diseases. TG-1801 has demonstrated encouraging pre-clinical anti-tumor activity both as a single agent and in combination with anti-CD20 monoclonal antibodies. With the addition of TG-1801 to our pipeline, we now have three targeted immunotherapies in-house that can potentially be used together to create a novel non-chemo treatment option that uses the body’s immune system to fight B-cell cancers, including NHL and CLL."